BI-RADS (Breast Imaging Reporting and Data System) is the ACR standard for describing breast imaging findings and assigning assessment categories (0–6) with management recommendations.

Which modalities are supported?

Mammography, ultrasound, and MRI, using ACR BI-RADS 5th edition descriptors, with kinetic curve analysis and multi-finding support.

Is this a medical device?

No. It is for educational and research purposes only, is not a regulatory-cleared medical device, and does not replace professional medical judgment.

Aperivue RADS

Breast Imaging Report Generator

Structured reporting with BI-RADS assessment · Mammography, Ultrasound & MRI · PACS-ready output

Indication

Comparison

Breast Composition (Mammography)

Findings

Finding label

Location

Laterality

Clock position

Depth

Distance from nipple (mm)

Size (cm)

Descriptors

Finding type

BI-RADS Assessment

Notes (optional)

Other Findings

Report Preview

Impression (editable — clear to auto-generate)

MAMMOGRAPHY

COMPARISON: None available.

FINDINGS:

1. Finding 1:

IMPRESSION:
Mammography: BI-RADS 1. Negative.

BI-RADS — assessment categories

Malignancy risk and management by ACR BI-RADS Atlas 5th Edition category. The same values drive this calculator.

Category	Malignancy risk	Management
BI-RADS 0	N/A	Additional imaging evaluation needed and/or prior mammograms for comparison.
BI-RADS 1	Essentially 0%	Routine screening.
BI-RADS 2	Essentially 0%	Routine screening.
BI-RADS 3	>0% but ≤2%	Short-interval (6-month) follow-up.
BI-RADS 4A	>2% to ≤10%	Tissue sampling.
BI-RADS 4B	>10% to ≤50%	Tissue sampling.
BI-RADS 4C	>50% to <95%	Tissue sampling.
BI-RADS 5	≥95%	Tissue sampling.
BI-RADS 6	N/A	Surgical excision when clinically appropriate.

Key category rules

BI-RADS assessment categories are shared across mammography, ultrasound, and MRI; the same 0–6 scale applies to every modality.
BI-RADS 0 is an incomplete assessment — additional imaging and/or prior studies for comparison are needed before a final category is assigned.
BI-RADS 3 (probably benign) implies a >0% to ≤2% malignancy risk and is managed with short-interval (typically 6-month) follow-up rather than immediate biopsy.
BI-RADS 4 is subdivided into 4A, 4B, and 4C by increasing suspicion (>2–≤10%, >10–≤50%, and >50–<95% respectively), all warranting tissue sampling.
BI-RADS 5 carries a ≥95% malignancy risk; BI-RADS 6 denotes biopsy-proven malignancy already established before imaging.